Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00725127 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chronotherapy with Low-dose Aspirin for Primary Prevention

Study acronym: CARING
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 6, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Dec 2025 to Dec 31, 2025
    • Study completion date: Jun 2026 to Jun 30, 2026
    • Site details revised at 19 of 19 sites
    v20
  2. Minor 3 versions Re-verified since Nov 2, 2020, no change to tracked fieldsv17-v19
  3. Notable Primary completion date: Dec 2020 to Dec 2025
    • Study completion date: Jun 2021 to Jun 2026
    v16
  4. Minor Study sites: 20 to 19v15
  5. Notable Primary completion date: Dec 2018 to Dec 2020
    • Study completion date: Jun 2019 to Jun 2021
    v14
Show 12 earlier versionsHide 12 earlier versions
  1. Minor 4 versions Re-verified since Mar 18, 2014, no change to tracked fieldsv10-v13
  2. Notable Primary completion date: Dec 2016 to Dec 2018
    • Study completion date: Jun 2017 to Jun 2019
    v9
  3. Minor 4 versions Re-verified since Aug 3, 2010, no change to tracked fieldsv5-v8
  4. Minor Study Identification, Study Statusv4
  5. Minor Re-verified, no change to tracked fieldsv3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 19 to 20
    • Start date: Sep 2008 to Oct 2008
    v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
8,786 trials monitored
See 412 trials at risk
5,087 trials monitored
See 222 trials at risk
3,531 trials monitored
See 153 trials at risk
and 2 more diseases
Brief summary: Aspirin (ASA) has been shown to provide marked benefits in primary and secondary prevention of cardiovascular events. Substantial evidence suggests that low-dose ASA therapy should also be used as a primary prevention strategy in men and women with diabetes who are at high cardiovascular risk. On the other hand, there is current evidence on the potential benefits of low-dose ASA therapy in subjects with impaired fasting glucose, including those with metabolic syndrome. Most important, previous laboratory animal and clinical trial research convincingly demonstrates administration time-dependent (with reference to circadian rhythms) effects of ASA. Thus, the effects of ASA upon lipoperoxides, b-adrenergic receptors, and blood pressure (BP) in clinically healthy subjects depend on the circadian timing of ASA administration. The administration-time-dependent influence of ASA on BP was previously demonstrated in a randomized trial on healthy women and other independent double-blind, randomized, placebo-controlled clinical trials conducted, first, on clinically healthy subjects, a second one on normotensive and hypertensive subjects, a third one on pregnant women at high risk for preeclampsia and a fourth one in previously untreated patients with mild hypertension. The findings of these BP studies are consistent; BP-lowering effect of low-dose ASA is achieved when administered at bedtime but not upon awakening. In keeping with the chronopharmacological effects of ASA and the previous findings suggesting that ASA at low dose may exert a potential beneficial effect on BP, endothelium function and cardiovascular function, this prospective, randomized, parallel-arm study will investigate the potential influence of ASA on the primary prevention of cardiovascular, cerebrovascular and renal events in subjects with either impaired fasting glucose (≥ 100 mg/dl) or previous diagnosis of type 2 diabetes mellitus, who will receive low-dose ASA (100 mg/day) at different circadian times (upon awakening or at bedtime) in relation to their rest-activity cycle.
Trial Details
NCT Number NCT00725127
Lead Sponsor University of Vigo
Conditions
(from sponsor)
Type 2 Diabetes
Related terms Angina Pectoris, Diabetes Mellitus, Type 2, Myocardial Infarction, Renal Insufficiency, Chronic, Stroke
Enrollment 3,200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov